Intracoronary vs intravenous abciximab in interventional cardiology: A reopened question?

Vascul Pharmacol. 2015 Oct:73:8-10. doi: 10.1016/j.vph.2015.08.001. Epub 2015 Aug 5.

Authors

Marco Zimarino¹, Francesco Radico², Steen Dalby Kristensen³, Raffaele De Caterina²

Affiliations

¹ Institute of Cardiology and Center of Excellence on Aging, "G. d'Annunzio" University, Chieti, Italy. Electronic address: m.zimarino@unich.it.
² Institute of Cardiology and Center of Excellence on Aging, "G. d'Annunzio" University, Chieti, Italy.
³ Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark.

PMID: 26254107
DOI: 10.1016/j.vph.2015.08.001

No abstract available

Keywords: Coronary intervention; Glycoprotein IIb–IIIa inhibitors.

Publication types

Review

MeSH terms

Abciximab
Administration, Intravenous
Antibodies, Monoclonal / administration & dosage*
Antibodies, Monoclonal / adverse effects
Antibodies, Monoclonal / pharmacokinetics
Coronary Thrombosis / blood
Coronary Thrombosis / etiology
Coronary Thrombosis / prevention & control*
Humans
Immunoglobulin Fab Fragments / administration & dosage*
Immunoglobulin Fab Fragments / adverse effects
Percutaneous Coronary Intervention* / adverse effects
Platelet Aggregation Inhibitors / administration & dosage*
Platelet Aggregation Inhibitors / adverse effects
Platelet Aggregation Inhibitors / pharmacokinetics
Treatment Outcome

Substances

Antibodies, Monoclonal
Immunoglobulin Fab Fragments
Platelet Aggregation Inhibitors
Abciximab